Lung Cancer
Издатель: Elsevier · ISSN 0169-5002 · 73 статей
- Severe hepatic injury or immune-related hepatitis? Reconsidering the hepatic safety signal in HBsAg-positive lung cancer
- Removal notice to “Characterization of a rare EGFR resistance mutation in a lung cancer patient with a long response to osimertinib: case report” [Lung Cancer 218 (2026) 109489]
- Changes in HER2 protein expression before and after EGFR TKI therapy in EGFR-mutant non-small cell lung cancer: a real world paired-biopsy study
- Rethinking the clock: Is treatment-free interval truly predictive of platinum sensitivity in small-cell lung cancer?
- Histology-specific immune toxicity patterns of checkpoint inhibitors in thymic epithelial tumours: A systematic review, meta-analysis, and pharmacovigilance study
- Contents
- The management of complex patients with inoperable stage III NSCLC: practical lessons from case-based discussion
- Artificial intelligence–based assessment of tumor bed stroma in non–small cell lung cancer after neoadjuvant therapy: Association with pathologic response and survival. A multicenter study
- Subtyping limited stage small cell lung cancer (LS SCLC) reveals inflammatory subtypes with improved chemoradiotherapy outcomes
- Non-small cell lung cancer with synchronous oligometastatic disease at the time of initial diagnosis. Impact of multimodal treatment on prognosis
- Long-term real-world outcomes of nivolumab+ipilimumab treatment of unresectable pleural mesothelioma: update of Meso-Immune GFPC 04-2021 study
- Artificial Intelligence–Based Assessment of Pathologic Response to Neoadjuvant Chemoimmunotherapy in Non–Small Cell Lung Cancer: An International Multicenter Cohort Study
- Treatment-free interval as a determinant of second-line chemotherapy outcomes in extensive-stage small cell lung cancer: a Dutch population-based study
- The efficacy and feasibility of neoadjuvant immunochemotherapy versus chemotherapy in Limited-Stage Small-Cell lung cancer
- Molecular concordance and clonal dynamics of KRAS mutations in lung adenocarcinoma across distinct clinical scenarios
- Characterization of the genomic and transcriptomic landscape of invasive non-mucinous lung adenocarcinoma based on IASLC grading
- Reassessing surgical resection in small cell lung cancer in the multimodal treatment era
- Discordance in pleural mesothelioma response classification and modelling of impact on clinical trials
- Systemic therapy and radiotherapy for small-cell lung cancer brain metastases
- Cardiovascular outcomes and mortality risk associated with GLP-1 RAs vs. SGLT-2 inhibitors in patients with incident lung cancer: A target trial emulation
- Standard targeted therapy implementation for driver alterations newly identified by comprehensive genomic profiling in clinically driver-negative advanced NSCLC
- Change in the incidence of medication-related osteonecrosis of the jaw in lung cancer patients receiving bone modifying agents with immune checkpoint inhibitors
- First-line camrelizumab plus chemotherapy followed by camrelizumab-apatinib maintenance for ES-SCLC: a single-arm phase II study
- Long-term efficacy and adherence of a lung cancer screening strategy with extended LDCT intervals: Results from the BioMILD trial
- Outcomes of long-term responders to immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). A retrospective regional study
- Robotic-assisted bronchoscopic biopsy and EBUS-TBNA in lung cancer: An outcome comparison between clinical and pathological staging
- Time-dependent impact of programmed death-ligand 1 expression on early progression and long-term response to first-line osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer
- More than a risk factor: alcohol use following diagnosis in non-small cell lung cancer patients
- Pathological complete necrosis after pulmonary thermal ablation: a systematic review and meta-analysis of ablate-and-resect studies
- Longitudinal transcriptomic profiling of paired early and metastatic EGFR-mutant lung adenocarcinomas reveals molecular programs associated with disease progression